Caverject Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
Caverject (alprostadil) is used to treat erectile dysfunction (impotence) and to help diagnose certain causes of this disorder. It is also used to improve blood flow in newborn babies with a certain genetic heart condition. This drug is a naturally occurring form of prostaglandin. This medication is available in generic form. Common side effects include mild/moderate pain, irritation, or slight bleeding at the injection site.
The dose of Caverject is individualized for each patient under supervision of a physician. Doses of greater than 60 mcg are not recommended. Caverject may interact with nitroglycerin, hydralazine, or blood thinners. Tell your doctor all medications you use. This medication is not for use by women; therefore it is unlikely to be used during pregnancy or breast-feeding. It is recommended men use a condom to prevent transfer of this medication to a sexual partner if she is pregnant or could become pregnant.
Our Caverject (alprostadil) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Patient Information in Detail?
Easy-to-read and understand detailed drug information and pill images for the patient or caregiver from Cerner Multum.
Caverject in Detail - Patient Information: Side Effects
Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Stop using alprostadil and call your doctor at once if you have any of these serious side effects:
- feeling light-headed, fainting;
- bleeding from your urethra;
- bleeding, bruising, or swelling where you injected the medication;
- a painful erection that lasts 4 hours or longer;
- severe pain or irritation of your penis or urethra; or
- redness, lumps, tenderness, unusual shape or curving of the erect penis.
Less serious side effects may include:
- pain in your penis, urethra, or testicles;
- headache, dizziness;
- back pain;
- a rash on the skin of your penis;
- warmth or numbness of your penis; or
- cough, stuffy nose, cold symptoms.
Your sexual partner may also experience side effects such as burning, itching, or irritation of the body areas that come into contact with your penis.
This is not a complete list of side effects and others may occur. Tell your doctor about any unusual or bothersome side effect. You may report side effects to FDA at 1-800-FDA-1088.
Read the entire detailed patient monograph for Caverject (Alprostadil Injection) »
What is Patient Information Overview?
A concise overview of the drug for the patient or caregiver from First DataBank.
Caverject Overview - Patient Information: Side Effects
Remember that your doctor has prescribed this medication because he or she has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.
Tell your doctor immediately if any of these unlikely but serious side effects occur: redness/tenderness/swelling of the penis, lumps/unusual curving of the penis.
In the very unlikely event you have a painful or prolonged erection lasting 4 or more hours, stop using this drug and seek immediate medical attention, or permanent problems could occur.
A very serious allergic reaction to this drug is rare. However, seek immediate medical attention if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.
This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.
In the US -
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.
Read the entire patient information overview for Caverject (Alprostadil Injection)»
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Caverject FDA Prescribing Information: Side Effects
Local Adverse Reactions: The following local adverse reaction information was derived from con- trolled and uncontrolled studies, including an uncontrolled 18-month safety study.
Local Adverse Reactions Reported by ≥ 1% of Patients
Treated with CAVERJECT (alprostadil injection) for up to 18 Months*
N = 1861
N = 1861
|Penile pain||37%||Penis disorder***||3%|
|Prolonged erection||4%||Injection site ecchymosis||2%|
|Penile fibrosis**||3%||Penile rash||1%|
|Injection site hematoma||3%||Penile edema||1%|
| * Except for penile pain (2%), no significant local adverse
reactions were reported by 294 patientswho received 1 to 3 injections of
** See General Precautions.
*** Includes numbness, yeast infection, irritation, sensitivity, phimosis, pruritus, erythema, venous leak, penile skin tear, strange feeling of penis, discoloration of penile head, itch at t ip of penis.
Penile Pain: Penile pain after intracavernosal administration of CAVERJECT (alprostadil injection) was reported at least once by 37% of patients in clinical studies of up to 18 months in duration. In the majority of the cases, penile pain was rated mild or moderate in intensity. Three percent of patients discontinued treatment because of penile pain. The frequency of penile pain was 2% in 294 patients who received 1 to 3 injections of placebo.
Prolonged Erection/Priapism: In clinical trials, prolonged erection was defined as an erection that lasted for 4 to 6 hours; priapism was defined as erection that lasted 6 hours or longer. The frequency of prolonged erection after intracavernosal administration of CAVERJECT (alprostadil injection) was 4%, while the frequency of priapism was 0.4%. In the majority of cases, spontaneous detumescence occurred. To minimize the chances of prolonged erection or priapism, CAVERJECT (alprostadil injection) should be titrated slowly to the lowest effective dose (see DOSAGE AND ADMINISTRATION section). The patient must be instructed to immediately report to his physician or, if unavailable, to seek immediate medical assistance for any erection that persists for longer than 4 hours. If priapism is not treated immediately, penile tissue damage and permanent loss of potency may result.
Hematoma/Ecchymosis: The frequency of hematoma and ecchymosis was 3% and 2%, respectively. In most cases, hematoma/ecchymosis was judged to be a complication of a faulty injection technique. Accordingly, proper instruction of the patient in self-injection is of importance to minimize the potential of hematoma/ecchymosis (see DOSAGE AND ADMINISTRATION).
The following local adverse reactions were reported by fewer than 1% of patients after injection of CAVERJECT (alprostadil injection) : balanitis, injection site hemorrhage, injection site inflammation, injection site itching, injection site swelling, injection site edema, urethral bleeding, penile warmth, numbness, yeast infection, irritation, sensit ivity, phimosis, pruritus, erythema, venous leak, painful erect ion, and abnormal ejaculation.
Systemic Adverse Events: The following systemic adverse event information was derived from controlled and uncontrolled studies, including an uncontrolled 18-month safety study.
Systemic Adverse Events Reported by ≥ 1% of Patients Treated
with CAVERJECT (alprostadil injection) for up to 18 Months*
|Body System/Reaction|| CAVERJECT
N = 1861
|Body System/Reaction|| CAVERJECT
N = 1861
|Cardiovascular System||Urogenital System|
|Central Nervous System||Miscellaneous|
|Upper respiratory infection||4%|
| * No significant adverse events were reported
by 294 patients who received 1 to 3 injections ofplacebo.
** prostatitis, pain, hypertrophy, enlargement
*** pain in various anatomical structures other than injection site
**** injuries, fractures, abrasions, lacerations, dislocations
The following systemic events, which were reported for < 1% of patients in clinical studies, were judged by investigators to be possibly related to use of CAVERJECT (alprostadil injection) : testicular pain, scrotal disorder, scrotal edema, hematuria, testicular disorder, impaired urination, urinary frequency, urinary urgency, pelvic pain, hypotension, vasodilation, peripheral vascular disorder, supraventricular extrasystoles, vasovagal reactions, hypesthesia, non-generalized weakness, diaphoresis, rash, non-application site pruritus, skin neoplasm, nausea, dry mouth, increased serum creatinine, leg cramps, and mydriasis.
Hemodynamic changes, manifested as decreases in blood pressure and increases in pulse rate, were observed during clinical studies, principally at doses above 20 micrograms and above 30 micrograms of alprostadil, respectively, and appeared to be dose-dependent. However, these changes were usually clinically unimportant; only three patients discontinued the treatment because of symptomatic hypotension.
CAVERJECT (alprostadil injection) had no clinically important effect on serum or urine laboratory tests.
No information provided.
Read the entire FDA prescribing information for Caverject (Alprostadil Injection) »
Additional Caverject Information
Caverject - User Reviews
Caverject User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Sex & Relationships
Get tips to boost your love life.